The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation
From MaRDI portal
Publication:856106
DOI10.1016/j.amc.2006.01.061zbMath1101.92026OpenAlexW2026154594MaRDI QIDQ856106
Alberto d'Onofrio, Alberto Gandolfi
Publication date: 7 December 2006
Published in: Applied Mathematics and Computation (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.amc.2006.01.061
Medical applications (general) (92C50) Qualitative investigation and simulation of ordinary differential equation models (34C60) Global stability of solutions to ordinary differential equations (34D23)
Related Items (10)
A bi-parametric model for the tumour angiogenesis and antiangiogenesis therapy ⋮ Multi-input optimal control problems for combined tumor anti-angiogenic and radiotherapy treatments ⋮ Analysis of the Hopf bifurcation for the family of angiogenesis models. II: The case of two nonzero unequal delays ⋮ Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function ⋮ Stability analysis of the family of tumour angiogenesis models with distributed time delays ⋮ On an extension of a mathematical model for tumor anti-angiogenesis ⋮ Resonance of the epidemic threshold in a periodic environment ⋮ Tumor Development Under Combination Treatments with Anti-angiogenic Therapies ⋮ On optimal delivery of combination therapy for tumors ⋮ Effect of treatment on the global dynamics of delayed pathological angiogenesis models
Cites Work
- Periodic motions
- Globally stable vaccine-induced eradication of horizontally and vertically transmitted infectious diseases with periodic contact rates and disease-dependent demographic factors in the population
- Stability properties of pulse vaccination strategy in SEIR epidemic model
- Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999)
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
This page was built for publication: The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation
